Skip to content

Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy

Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04861142
Enrollment
350
Registered
2021-04-27
Start date
2021-04-23
Completion date
2024-10-31
Last updated
2021-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Brief summary

Osteoporosis and osteoporotic fractures, especially hip fractures, have a significant impact on public healthcare. Despite the fact that the patients that have suffered an osteoporotic fracture have 86% increased risk of sustaining a second osteoporotic fracture, the efforts to prevent these fractures remain inadequate. The in-hospital initiation of antiosteoporotic treatment in patients that have been admitted due to hip fracture has shown to improve treatment rates and contribute to second fracture prevention. For this purpose the Arbeitsgemeinschaft für Osteosynthesefragen (AO) Foundation has introduced an algorithm that can be used by Orthopedic surgeons for the prevention of second fracture in patients that have already suffered an osteoporotic fracture. The purpose of this thesis is to study the efficacy of this algorithm in preventing the second fracture in the greek population. The study will include patients that have been admitted in the Orthopedics department of the University Hospital of Heraklion due to hip fracture. Bone density measurement will be performed using the DXA method and antiosteoporotic treatment will be administered according to the algorithm. These patients will be included in the hip registry of the Orthopedics department and the follow-up will last for 2 years .The primary aims of the study are: a)evaluation of the adherence to the antiosteoporotic medication b)the efficacy of the adherence to the aforementioned clinical algorithm in the secondary fracture prevention in the greek population.

Interventions

DRUGAnti-osteoporotic medication( alendronate or denosumab)

Initiation of anti-osteoporotic medication (alendronate or denosumab)

Sponsors

University General Hospital of Heraklion
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Patients with hip fractures after low-energy falls(fragility fractures)

Exclusion criteria

-Patients with hip fractures after high energy falls

Design outcomes

Primary

MeasureTime frame
Adherence to the prescribed anti-osteoporotic medication1 year
Secondary fracture incidence1 year

Secondary

MeasureTime frame
Morbidity and mortality of operatively treated hip fractures in our department1 year

Countries

Greece

Contacts

Primary ContactTheodoros Tosounidis, Assistant Professor
ttosounidis@yahoo.com+30 2810395055
Backup ContactIoannis Daskalakis, Orthopaedic Surgery Resident
g_dask@hotmail.gr+30 6973324328

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026